Form 8-K - Current report:
SEC Accession No. 0001104659-23-039748
Filing Date
2023-03-31
Accepted
2023-03-31 09:18:45
Documents
12
Period of Report
2023-03-31
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2310923d1_8k.htm   iXBRL 8-K 29331
  Complete submission text file 0001104659-23-039748.txt   206448

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA anvs-20230331.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE anvs-20230331_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anvs-20230331_pre.xml EX-101.PRE 22599
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2310923d1_8k_htm.xml XML 3707
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 23783621
SIC: 2834 Pharmaceutical Preparations